Drug Profile
Research programme: COMT inhibitors - Avalo Therapeutics
Alternative Names: AVTX-406; CERC 425; CERC-406Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Avalo Therapeutics
- Class Antidepressants; Antiparkinsonians; Small molecules
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders; Parkinson's disease
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 09 Jun 2021 ES Therapeutics in-licenses COMTi platform including AVTX 406 from Cerecor